HC Wainwright Brokers Increase Earnings Estimates for VTYX

Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) - Stock analysts at HC Wainwright boosted their FY2024 EPS estimates for shares of Ventyx Biosciences in a research note issued on Tuesday, January 14th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($2.18) for the year, up from their prior estimate of ($2.19). HC Wainwright has a "Neutral" rating on the stock. The consensus estimate for Ventyx Biosciences' current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Ventyx Biosciences' Q1 2025 earnings at ($0.71) EPS, Q2 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($0.99) EPS, FY2025 earnings at ($3.43) EPS, FY2026 earnings at ($2.63) EPS, FY2027 earnings at ($1.98) EPS and FY2028 earnings at ($1.56) EPS.

Separately, Oppenheimer reiterated an "outperform" rating and set a $9.00 price target (down from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $10.00.

Ventyx Biosciences Stock Performance

Shares of NASDAQ VTYX traded up $0.13 during midday trading on Friday, reaching $2.02. 2,276,739 shares of the stock were exchanged, compared to its average volume of 2,005,949. The company has a 50 day simple moving average of $2.27 and a 200 day simple moving average of $2.27. The stock has a market capitalization of $142.83 million, a P/E ratio of -0.86 and a beta of 0.55. Ventyx Biosciences has a twelve month low of $1.67 and a twelve month high of $11.48.

Hedge Funds Weigh In On Ventyx Biosciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Palumbo Wealth Management LLC purchased a new stake in shares of Ventyx Biosciences during the third quarter worth $26,000. China Universal Asset Management Co. Ltd. grew its stake in Ventyx Biosciences by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company's stock worth $30,000 after purchasing an additional 5,310 shares in the last quarter. Intech Investment Management LLC purchased a new stake in Ventyx Biosciences during the 3rd quarter worth about $42,000. The Manufacturers Life Insurance Company raised its position in Ventyx Biosciences by 41.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company's stock valued at $56,000 after purchasing an additional 7,096 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Ventyx Biosciences in the 2nd quarter valued at about $58,000. Hedge funds and other institutional investors own 97.88% of the company's stock.

Insider Activity at Ventyx Biosciences

In other Ventyx Biosciences news, CEO Raju Mohan purchased 261,752 shares of Ventyx Biosciences stock in a transaction dated Monday, November 25th. The shares were acquired at an average price of $2.01 per share, with a total value of $526,121.52. Following the completion of the transaction, the chief executive officer now owns 2,175,028 shares of the company's stock, valued at $4,371,806.28. This trade represents a 13.68 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider John Nuss sold 21,119 shares of the firm's stock in a transaction that occurred on Friday, December 27th. The shares were sold at an average price of $2.36, for a total transaction of $49,840.84. Following the completion of the transaction, the insider now directly owns 464,582 shares of the company's stock, valued at approximately $1,096,413.52. The trade was a 4.35 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders purchased 630,000 shares of company stock worth $1,262,415. Insiders own 18.18% of the company's stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.